Marine bioactive peptides — especially salmon-derived ProGo® — are emerging as a clinically studied ingredient class for metabolic support. Here is an honest look at the science: what these peptides are, how they interact with GLP-1 and related pathways, and what the published research actually shows (including its limitations).
Bioactive peptides are short chains of amino acids — the building blocks of protein — that can activate specific receptors and signal functions in the body. Unlike whole proteins, their small size allows them to reach target receptors quickly. Marine and salmon-derived bioactive peptides are a clinically studied ingredient class shown in laboratory (in-vitro) research to interact with metabolic pathways including GLP-1 and GIP.
All proteins are made of amino acids chained together. When your digestive system breaks down protein — from a piece of salmon, a steak, or a whey shake — it does not always produce free-floating amino acids. Sometimes it produces short segments of those chains, typically two to thirty amino acids long. These fragments are called peptides.
A peptide is called bioactive when it does something beyond providing nutrition. Certain peptide sequences act as molecular messengers: they can bind to receptors on cell surfaces, cross intestinal membranes, and trigger signaling cascades that affect hunger, digestion, insulin response, inflammation, and more.
The concept is not new. Casomorphins (from milk) and glutathione (from many foods) are among the best-known food-derived bioactive peptides studied for decades. What is newer is the systematic investigation of marine and salmon-derived peptides — specifically for their potential role in metabolic signaling pathways relevant to weight management.
Atlantic salmon (Salmo salar) offers a favorable amino acid profile for generating bioactive peptides. Salmon protein is rich in sequences that, once liberated by enzymatic hydrolysis, may yield peptides capable of interacting with gut hormone receptors. Norwegian Atlantic salmon — farmed in cold, clean fjord water — is the source for ProGo®, the bioactive peptide ingredient at the heart of triGLP.
The peptides are extracted through a controlled enzymatic hydrolysis process. The result is a salmon protein hydrolysate (SPH) that concentrates the bioactive fractions of the fish — and can be standardized across batches, which is a prerequisite for meaningful research.
To understand why researchers are interested in salmon peptides for metabolic support, you need to understand the three pathways they are studied against: GLP-1, GLP-2, and GIP. These are incretin hormones — chemical messengers released by your gut after you eat.
Glucagon-like peptide-1 (GLP-1) is produced by L-cells in the small intestine and colon in response to food. Once released, it travels through the bloodstream and activates GLP-1 receptors in multiple tissues:
GLP-1's half-life in the bloodstream is roughly one to two minutes before the enzyme DPP-4 degrades it. This is why supporting the body's natural GLP-1 production — rather than introducing it externally — is an appealing nutritional research target.
GLP-2 (glucagon-like peptide-2) is co-secreted with GLP-1 from the same L-cells and targets the intestinal epithelium. It promotes gut-lining repair and integrity, reduces intestinal permeability, and plays a role in nutrient absorption efficiency. A healthy gut lining is foundational to any weight-management strategy: if the gut cannot absorb nutrients properly, metabolic signals downstream can go haywire.
Glucose-dependent insulinotropic polypeptide (GIP) is released from K-cells in the upper small intestine. Like GLP-1 it amplifies insulin release after meals, but it also influences fat storage in adipose tissue and plays a role in bone metabolism. Together, GLP-1 and GIP account for the majority of the meal-stimulated insulin response in healthy individuals — a phenomenon called the "incretin effect."
Signals fullness to the brain, slows gastric emptying, and helps regulate blood-sugar-driven hunger cues after meals.
Supports the intestinal lining and promotes efficient nutrient absorption — the metabolic foundation.
Amplifies the insulin response after meals and helps regulate how the body partitions energy from food.
ProGo® is a patented bioactive peptide ingredient derived from sustainably sourced Norwegian Atlantic salmon, developed and manufactured by Hofseth BioCare ASA (Oslo Børs: HBC), a Norwegian biotechnology company specializing in marine-derived bioactive ingredients.
Hofseth BioCare produces ProGo® through enzymatic hydrolysis of salmon protein — a process that breaks the full-length proteins into shorter peptide fractions. The specific peptide sequences that result from this hydrolysis are what give ProGo® its proposed bioactive properties. The ingredient is:
ProGo® holds FDA New Dietary Ingredient (NDI) status — meaning the FDA has reviewed the ingredient's safety dossier and has not objected to its use as a dietary ingredient. The FDA has also not objected to 13 structure/function claims submitted for ProGo® — these are "supports" and "helps maintain" claims, not disease-treatment claims, and they describe the ingredient, not any finished product.
The exclusive rights to commercialize ProGo® through multi-level marketing channels were licensed to Fission Holdings LLC (Tulsa, OK) effective May 22, 2026 — with ORYGN holding a sublicense. triGLP drops and Ignite powder are the first finished products to bring this ingredient to retail and MLM consumers.
One important distinction the science makes clear: the published research has primarily used the powder/hydrolysate form (SPH). The drops format in triGLP is a concentrated extract. Dose-equivalence between the drops and the studied powder doses is inferred, not independently tested in human trials — and we will say so plainly rather than overclaim.
triGLP delivers ProGo® salmon-derived bioactive peptides as sublingual drops — supporting GLP-1, GLP-2 & GIP pathways naturally.
Shop triGLP →The research program behind ProGo® spans more than a decade and more than $50 million in investment across Hofseth BioCare's portfolio. When reviewing the evidence, we follow the same discipline we ask you to apply: label study type, name the population, and do not extrapolate beyond what was tested.
All study references below describe the ProGo® ingredient — a clinically studied ingredient — and are provided for informational purposes only. They do not constitute claims about triGLP as a finished product. Individual results vary.
Currie et al., "Initial Exploration of the In Vitro Activation of GLP-1 and GIP Receptors by Salmon-Derived Bioactive Peptides" — NCBI/PMC PMC11595994
In this cell-assay study, researchers tested how the smallest peptide fractions derived from salmon protein hydrolysate interacted with GLP-1 and GIP receptors in isolated cell lines. The smallest peptide fractions demonstrated receptor-activating activity in the cell model. This is the study most directly relevant to the GLP-1 and GIP mechanism proposed for ProGo®.
Limitation: in-vitro (cell-based) results do not automatically translate to the same effects in living humans. Cell receptors in a dish behave differently than receptors within the full complexity of human metabolism. This study does not establish that taking ProGo® will raise GLP-1 levels in the bloodstream at any given dose. It establishes a mechanistic hypothesis for further investigation.
Hofseth BioCare research program — Salmon Protein Hydrolysate (SPH) in overweight adults
The ProGo® research program includes peer-reviewed studies using the powder/hydrolysate form (SPH) in human subjects. The studied dose range is 4–8 g per day (sweet spot identified by the research), up to 16 g. The Ignite powder stick pack is formulated at the 4 g studied dose per serving — this is the format most directly aligned with the studied powder research.
Limitation: the triGLP drops are a concentrated extract. The exact dose of ProGo® per drop serving and its equivalence to the studied 4 g powder dose is inferred, not independently confirmed in a head-to-head human trial. "Clinically studied ingredient" is the accurate framing; "clinically proven product" is not.
Myostatin and Activin A signaling — muscle preservation mechanism
Separate research into ProGo® peptides explores their interaction with myostatin and Activin A — proteins that regulate muscle breakdown. In pre-clinical studies, certain salmon-derived peptide fractions have shown activity that may help support lean muscle preservation. This is the science behind triGLP's muscle-protection positioning: the goal of losing fat, not muscle.
Limitation: pre-clinical and mechanistic research establishes a plausible pathway; it does not guarantee the same magnitude of effect will be observed across all individuals in a randomized human trial. We use the language "studied for their role in supporting lean-muscle preservation" rather than "proven to prevent muscle loss."
13 FDA-recognized structure/function claims (NDI status)
ProGo® holds FDA New Dietary Ingredient status, meaning the ingredient passed the FDA's safety review process for dietary supplements. The 13 structure/function claims on file are statements like "supports healthy metabolism" and "helps maintain lean muscle" — claims the FDA reviewed and did not object to. This is distinct from FDA approval of a drug, and it is distinct from clinical proof of efficacy in humans.
NDI status and structure/function claims confirm safety review and regulatory standing. They do not mean the FDA has certified that the ingredient causes weight loss or any specific health outcome.
The ProGo® research program is published and peer-reviewed — the science is real. What science asks of us is to say what kind of evidence exists, for whom, and at what dose — without collapsing the distance between a promising cell study and a guarantee about what will happen in your body specifically.
That honesty is not a weakness. It is what E-E-A-T (experience, expertise, authoritativeness, trustworthiness) actually means: sources you can rely on because they tell you what they know and what they do not.
Figures describe the ProGo® research program and are provided for informational purposes only — not product claims. Read the full science at the ORYGN store →
The question "are peptides safe for weight loss?" covers a wide spectrum, because the word "peptides" encompasses very different things. It is important to distinguish between the categories:
ProGo® salmon-derived peptides are food-grade ingredients derived from salmon protein through enzymatic hydrolysis. The body encounters peptides derived from food protein every time it digests a meal — the mechanism is not foreign to human physiology. Because ProGo® holds FDA New Dietary Ingredient status, it has undergone the regulatory safety review required for new dietary ingredients in the United States.
The certifications attached to ProGo® — Non-GMO Project Verified, GMP, Kosher, Halal, HACCP, free from antibiotics, pesticides, and BSE/TSE — reflect meaningful manufacturing and quality standards. As a food-grade salmon extract, the ingredient does not carry the systemic side-effect profile associated with pharmaceutical agents.
Prescription GLP-1 medications are injectable synthetic peptide drugs regulated as pharmaceuticals. They deliver high pharmacological doses of GLP-1 receptor agonists directly into the bloodstream, producing effects — including significant side effects — that operate on a completely different magnitude than a dietary supplement. They require prescriptions, physician oversight, and carry their own benefit-risk profiles that are outside the scope of this article.
triGLP is not a drug. It does not introduce synthetic GLP-1 or any hormone into the body. It supports the body's own metabolic signaling pathways using food-derived peptides, taken as sublingual drops — a fundamentally different mechanism at a fundamentally different physiological scale.
As with any dietary supplement — even food-derived, well-studied ones — there are important caveats:
The safety profile of ProGo® as studied and its regulatory standing make it a well-credentialed dietary ingredient. It is not, however, a replacement for medical advice or medical management of any condition.
triGLP is the first finished product to bring ProGo® salmon-derived bioactive peptides to the market in a sublingual drop format. "Sublingual" means the drops are placed under the tongue, where a rich network of capillaries allows ingredients to be absorbed directly into the bloodstream — bypassing the first pass through the digestive tract that can degrade some bioactive compounds.
The suggested use is 3–5 drops, one to two times daily (always follow your product label, as this may be updated). The format is:
The Ignite powder, launching July 4, uses the same ProGo® ingredient at the exact 4 g dose used in the published human research. If you want to stay as close as possible to the studied dose in powder form, Ignite provides that option.
Both formats are available exclusively through ORYGN's official store. Full triGLP product details →
Regular protein (like a chicken breast or a scoop of whey) is made of long amino acid chains. Bioactive peptides are short fragments of those chains — typically two to thirty amino acids long — that can bind to specific receptors in the body and trigger signaling responses. Not all protein produces bioactive peptides; the specific sequence matters. ProGo® is produced by enzymatic hydrolysis of salmon protein, a process that preferentially releases the bioactive peptide fractions.
The evidence is nuanced. In-vitro (cell-based) studies — including Currie et al. published in PMC11595994 — demonstrate that salmon-derived peptide fractions can activate GLP-1 and GIP receptors in cell models. The ProGo® human research program includes peer-reviewed studies using the powder form (SPH). What the research supports is describing ProGo® as a clinically studied ingredient with mechanisms relevant to metabolic support. It does not support a blanket claim that taking any peptide supplement guarantees weight loss — results depend on diet, activity, individual metabolism, and many other factors. Individual results vary.
"Marine bioactive peptides" is the broader category — peptides derived from any marine source including fish, shellfish, seaweed, and marine invertebrates. "Salmon peptides" refers specifically to peptides derived from salmon protein. ProGo® falls into both categories: it is a marine bioactive peptide specifically derived from Norwegian Atlantic salmon (Salmo salar). Salmon is one of the most-studied sources in the marine peptide literature because of its favorable amino acid profile and the availability of industrial-scale, sustainably sourced Norwegian salmon.
In-vitro literally means "in glass" — studies performed in test tubes or on isolated cell lines, outside a living organism. In-vitro studies are valuable for establishing mechanistic hypotheses: they can show that a compound can bind to a receptor or trigger a response in a cell model. They cannot tell you what happens inside the full complexity of a living human body — with its digestive enzymes, blood-brain barrier, competing metabolic processes, and individual variation. The Currie et al. GLP-1/GIP receptor study is an in-vitro study. We label it as such because that is what the science requires.
No — these are fundamentally different things. Prescription GLP-1 medications are injectable synthetic peptide drugs that introduce pharmacological doses of GLP-1 receptor agonists directly into the bloodstream, producing strong and well-studied effects (as well as documented side effects) in the pharmaceutical dose range. ProGo® is a food-grade dietary ingredient derived from salmon protein that, in laboratory studies, has shown activity at GLP-1 and GIP receptors. triGLP is a dietary supplement, not a drug. It does not introduce synthetic GLP-1 into the body. The scale, mechanism, regulatory status, and risk profile are entirely different.
ProGo® salmon-derived peptides hold FDA New Dietary Ingredient status — the ingredient has passed the FDA's safety review process for dietary supplements. It is Non-GMO Project Verified, GMP certified, food-grade, and free from antibiotics, pesticides, and BSE/TSE risk. As with any supplement, consult a qualified healthcare provider before starting, especially if you are pregnant, nursing, have a fish allergy, or are taking prescription medications. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease.
Because metabolic regulation is not a single lever. GLP-1 governs appetite and satiety signaling. GLP-2 supports the gut lining and nutrient absorption — a foundational layer that affects how efficiently the rest of your metabolism works. GIP is part of the incretin effect that governs how your body responds to food with insulin. Prescription GLP-1 medications that also target GIP have shown superior metabolic outcomes in pharmaceutical trials compared to single-pathway agents. Supporting all three through a natural dietary ingredient is the scientific rationale behind triGLP's three-pathway approach. Learn more about GLP-1 →
Both use ProGo® salmon-derived bioactive peptides. The drops are a concentrated extract taken sublingually (under the tongue) — convenient, fast, and portable. The Ignite powder (launching July 4) is a cran-apple flavored stick pack formulated at 4 g of ProGo® per serving — the exact dose used in the published human research program. If you want your dose to align as closely as possible with what was studied in published research, Ignite is that format. Both are available from the official ORYGN store. See full triGLP details →
ProGo® salmon bioactive peptides in drops. Three pathways, one formula, no prescription needed.
Shop triGLP →